Patent Application
20100047766
The present invention concerns methods for manipulating and detecting analytes. The method relates in particular to methods for separating different analytes from the same sample. The invention is particularly advantageous, since its separation aspects allow a plurality of different analytes in a single sample to be detected, or separately manipulated.
It has been known to employ buoyant particles, and other types of particles (such as magnetic particles and high density particles) in methods of analysis, in particular in biological assays. In addition to this, methods using buoyant beads to remove waste from the surface of large volumes of water, such as swimming pools are also well-known and have been developed by MST (MicroScience Technologies). Typically, hollow particles that are buoyant and are capable of attaching to bacterial contaminants in the water via an antibody linked to the surface of the particle are mixed with the water and upon rising to the surface, the bacteria and particle mixture is ‘skimmed’ from the surface to detect the pool contaminants. This has been carried out for detection of cryptosporidium in swimming pools.
Methods for detecting analytes using magnetic particles, in particular magnetic beads, have been around for some time. For example, common assay methods use magnetic beads which are added to the sample to be assayed. The beads carry a ligand on their surface which enables them to bind specifically to a target analyte. A magnetic field is then applied, enabling the beads and the bound material to be separated from the rest of the sample. In many cases the analyte is then measured by detection of a fluorescence-based emission, and can be used in conjunction with flow cytometric analysis. Such methods have been used for in vitro diagnostics against desired targets such as cells, nucleic acids, proteins and other types of biomolecule.
However, these types of existing methods require several sample preparation steps. In particular, this invention allows for testing and separation of several analytes within one reaction volume, or platform in the case of a microfluidic system. Further, previous techniques have often required several reactions in parallel to achieve multi-analyte reactions, resulting in lack of consistency and irreproducibility of results. Also relevant to a microfluidic lab-on-a-chip system, or integrated sample analysis device, this capability allows analytes to be captured as a whole from the entire sample volume. The captured analytes can then be separated towards different processing modules within the sample. The advantage here is that the capture step is carried out on the full volume of the collected sample, rather than an aliquot of the sample, which is the case in most analytical systems where the sample is split. This means that at equal sensitivity, lower volumes of sample are needed, providing substantial benefits to the patient, who accordingly need not provide such a large specimen.
It is an aim of the present invention to solve the problems associated with known techniques, including those described above. It is a further aim of the invention to develop improved methods for processing analytes (such as separating analytes) and detecting analytes.
Accordingly, the present invention provides a method for separating two or more analytes in a fluid, which method comprises:
An example of the invention in operation is depicted in
In the context of the present invention, neutrally buoyant is a situation where 95% or more of the beads of a certain type (combination of density, recognition molecule and bound analyte) remain (do not leave whilst flowing) in a particular channel (functional conduit) of the platform.
Preferably, the separating conduit is connected to the binding zone by a connecting conduit along which the bound analytes are allowed to flow, until they reach the separating conduit. Typically, the connecting conduit forms the lowest functional conduit (or highest functional conduit in the ‘sinking’ embodiment) and at least one particle is thus neutrally buoyant in the fluid that is used as a medium for binding and for transporting the bound analytes to the separating conduit (as shown in
It will be understood that it is a particularly preferred feature of the present invention that successively higher functional conduits contain successively lower density fluids, that is to say that the fluid density in each successively higher conduit becomes progressively lower (or vice versa in the ‘sinking’ embodiment). However, this feature is not essential. For example in the case of two analytes and three conduits (a high density conduit situated between two lower density conduits) separation will still be effective if the lowest conduit has a higher density fluid than the highest conduit, provided that one analyte has neutral buoyancy in the lowest conduit, and will thus remain there, whilst the second analyte has neutral buoyancy in the highest conduit, and will rise through the lowest and central conduit into the highest conduit. Nevertheless, this is a less efficient configuration and it is much preferred in a normal situation that the fluid density in each successively higher conduit becomes progressively lower in order that the most efficient separation can be achieved.
The functional conduits are not especially limited, provided that they are each capable of containing their fluid, without it mixing with fluid from a connecting functional conduit at the connecting locations. Generally, the conduits are of dimensions typical in microfluidic devices, since these dimensions are particularly suitable for reducing turbulence in the flowing fluids, and thus minimising any tendency to mixing at the locations where there is fluid connection between the functional conduits. Typical conduit dimensions are around 50-1000 μm. In fact, on this scale mixing at the fluid connection points is minimal, and certainly insufficient to have an adverse effect on the separation process (see Kamholz, A. E., Weigl, B. H., Finlayson, B. A. & Yager, P. “Quantitative analysis of molecular interaction in a microfluidic channel: The T-sensor.” Analytical Chemistry 71, 5340-5347, 1999).
As mentioned above, the functional conduits are in fluid connection with each other in order to achieve separation. These fluid connections are not especially limited provided that they are of sufficient size to allow passage of the particles and analytes from one functional conduit to the next, but not so large that mixing of fluids of different density occurs. Preferably the connections are slightly longer than the width of the channels, and form an open window on the whole of the superior surface (shadow cast vertically by the shape of the channel transporting the fluid) of the channel where the beads are in motion.
In the present method, the fluid may be any suitable fluid. Preferably, the fluid is an aqueous fluid.
In a preferred embodiment of the method, after step (a), the method further comprises transporting the bound analyte from one or more of the separate functional conduits where separation has taken place, to a concentrating zone beneath one or more detection elements in the fluid.
Each particle employed in the method is attached to a recognition agent. The number of different recognition agents will depend on the number of analytes in the sample that are under investigation. Usually each different particle type is attached to a different recognition agent, to ensure that one type of analyte attaches to one type of particle, and the other types of analyte each attach to other different types of particle. In alternative embodiments, each particle may be attached to more than one recognition agent, so that the analytes are separated into groups rather than individual types. The recognition agents attached to a single particle may be the same (for example if it is desirable to increase the binding potential of the particle to the analyte, or to attach more than one analyte species to a single particle) or may be different (e.g. if it is desirable to attach any of the analytes under investigation to any of the particles). In some of the latter embodiments, all of the different types of recognition agent in the system may be attached to a single particle so that any or all of the possible analytes may bind to a single particle.
In the present invention, the particles are not especially limited, provided that their function is not impaired. Preferably, the particles are selected from:
The latter particles may be used for the lowest level functional conduit, particularly if the lowest level conduit is formed from the connecting conduit such that the particles are not required to rise to collect in this conduit. Magnetic particles may also be employed, and are especially useful if variance in the buoyancy is desired, for example to fine tune the separation efficiency. However, typically sets of buoyant particles having differing buoyancies is desired, such as glass beads having a controlled range of buoyancies.
The method of the present invention is advantageous because it allows a more rapid separation (and detection) of analytes in a sample by reducing the number of processing steps conducted on the sample. Further, it reduces the amount of laboratory equipment required, making the method easier, and less costly, to perform. The invention is particularly advantageous, since its separation aspects allow a plurality of different analytes in a single sample to be detected, or separately manipulated. It also allows the whole of the sample to be accessed by each bead type, rather than having to split the sample into different aliquots which is the case in traditional testing methods. Once the analytes of interest have been captured by the recognition elements on the bead, and separated by the fluids present in the different conduits, they can easily be processed separately, potentially using very different methods. These properties are of particular interest on analytical instruments which carry out multi-analyte testing or on integrated lab-on-a-chip systems.
The present invention will be described by way of example only, with reference to the following Figure:
The invention will now be described in more detail.
The methods of the present invention may be employed to detect any type of analyte, provided that it may be attached to the particles. However, it is preferred that the methods are performed using a fluid that comprises a sample containing the analyte. Typically, the sample comprises a crude lysate of solid tissue, a crude lysate of a cell of cells, or a body fluid. More preferably, the sample comprises blood or a blood product or component. Most preferably, the sample comprises whole blood or blood plasma. Generally, the sample is from a mammal, such as a human. The term “analyte” is not particularly limiting. Suitable analytes may be any type of biomolecule which it is desired to detect in a sample. For example, the analyte may be a protein, prion, peptide, carbohydrate, DNA or RNA, or whole cell, virus or bacteria. In particular, the analyte may be an antigen, a viral protein, a bacterial protein, an antibody, a specific DNA and/or RNA sequence, or specific cell type. In specific embodiments of the present invention the analyte is related to the diagnosis and treatment (including the determination of theranostic information) of Hepatitis C, HIV or other viral pathogens.
The term “sample” is not especially limiting and refers to any specimen in which an analyte may be present. In particular, as already mentioned, the sample may be whole blood, urine or other body fluid, or a crude lysate of solid tissue or cells or supernatant from cultured cells. The sample may be subjected to processing steps before it is used in the present method.
The recognition agents referred to in the methods of the present invention are not especially limited. The particles may be coated with the recognition agent. The nature of the recognition agent is not especially limited, provided that it allows the particle to bind specifically to a target analyte. The recognition agent may be an antibody, specific for an antigen which may itself be the target analyte, or may be an antigen present on the surface of the target analyte. Alternatively, where the target analyte is a polynucleotide the recognition agent may be a polynucleotide sequence complementary to a section of the sequence of the analyte. In a further embodiment the recognition agent may be a lectin where the analyte is a carbohydrate. In a further embodiment the recognition agent may be a cell surface receptor and the analyte its ligand, agonist or antagonist. In a further embodiment the recognition agent may be an antibody or ligand and the analyte a cell or living organism with the appropriate antigenic determinant or receptor. Where there are two or more analytes under investigation, an antibody specific for each analyte may be employed, to ensure that one particle type attaches to one analyte and a different particle type attaches to another analyte. In this manner, a plurality of analytes can be processed in the same sample.
In the present methods the particle that is buoyant in the fluid is not especially limited. Buoyant particles suitable for use in the present invention are also commercially available. In particular the buoyant particle may be a hollow glass bead.
Magnetic particles suitable for use in the present invention are well known in the art. In particular, magnetic beads are commercially available for magnetic separation in a variety of sizes. In one embodiment the beads are super-paramagnetic beads. Preferably the particles do not have any remnant magnetism when not placed in a magnetic field to prevent aggregation of the particles, and to ease dispersal and mixing within the fluid.
The particles may also comprise a label to aid with their detection. Preferably, the label is a fluorescent label.
The detection element for detecting an analyte may comprises any detection element, provided that the element is suitable for detecting the analyte under investigation. Preferably, the element comprises one or more of a biosensor array, an electrochemical biosensor element, and an optical biosensor element.
In a further preferred embodiment of this method, in one or more detecting conduits, an analyte may be concentrated according to a concentrating method as described above.
The invention also provides a method for detecting one or more analytes, which method comprises:
Further provided is a method of diagnosing the presence of a pathogen in a subject, or detecting the presence of a genotype in a subject, which method comprises:
In this method, the pathogen is typically selected from a bacterium and a virus, or wherein the polypeptide is selected from a protein or a protein fragment, or the nucleic acid is selected from DNA and RNA. More preferably, the pathogen is HCV, HIV, rhinovirus, influenza virus or herpes virus. Typically, the subject is a mammal, such as a human. Typically the above listed viruses are human viruses.
Yet further provided is an apparatus for separating two or more analytes in a fluid, which apparatus comprises:
The apparatus of the invention is typically a flow cell type apparatus. In the apparatus of the present invention, the transporter generally comprises a pump for pumping the fluid from the binding zone.
Preferably the apparatus comprises at least one detecting element in at least one of the functional conduits. It is further preferred that the one or more detecting elements are situated above one or more concentrating zones. Typically, the detecting element is a biosensor or a micro array.
The invention will now be described by way of example only, with reference to the following specific embodiments.
Protocol for Samples that are to be Tested for HCV (this Protocol may also be Applied to HBV, HAV, HIV, Human Rhinovirus, Influenza Virus or Herpes Simplex Virus)
Nature of the Sample
Typically the sample is whole blood, serum, plasma, cell lysate or extraction (such as B cells or hepatocytes), nasopharyngeal mucous or urine. The sample may be conditioned to have a certain buffer composition, depending on the sample-type and its specific nature.
Bead Preparation
1 μg biotinylated antibody (other recognition agents, such as, oligonucleotides, PCR fragments, aptamers, PNA, lectins, antibody fragments, recombinant or purified receptors, and proteins may be employed as desired) to HCV El protein in 100 μl Phosphate Buffered Saline (PBS) or 1 μg biotinylated recombinant core protein antigen in 100 μl Phosphate Buffered Saline (PBS) or 1 μg biotinylated antibody to human Alanine aminotransferase (ALT) or 1 μg biotinylated antibody to human Aspartate aminotransferase (AST); are coupled to batches of 300 μl buoyant (MST technologies) beads of different densities at 20×106 beads/ml that have been coated with streptavidin by the manufacturer. The high affinity of biotin for streptavidin (Kd=10−14M) ensures a successful reaction and allows the antibodies to coat the surface of the beads. The reaction is washed of excess uncoupled antibody by centrifuging the beads for 5 min at 14,000 rpm, discarding the supernatant and replacing with fresh PBS. This wash step is repeated twice.
Binding Step
The sample with a volume of 1-5 ml is incubated for several minutes with the beads that are coupled with antibodies that have been raised to HCV surface proteins, HCV core proteins or biomarkers of liver health such as AST and ALT. This can also be achieved online, by flowing the sample at a rate of 0.1 to 5 ml/min over the beads in a chamber that allows retention of the sample (fritting material or filter) but permits the flow of solutions (preferred method). Through the same channel wash solution is passed after the sample, in a volume of 3 to 5 times the volume of the sample, to eliminate non-specific binding. This wash solution may contain detergents such as Triton X-100, Tween 20 or Nonidet P40 at concentrations of 0.01 to 1% that reduce the non-specific binding that can be observed in antibody-antigen interactions.
Flow through to Sorting Mechanism or Detection Area
A valve on the microfluidic system is opened to allow the flow through of particles towards the sorting area. Using low flow rates (0.01 to 1 ml/min) the beads are flowed through the system towards the system comprising fluids of different densities. These fluids of differing densities could be easily obtained by adding density agents such as glycerol to the serum. In such a case, lower percentages of glycerol would be diluted into the higher conduits into a buffer such as PBS supplemented with 1% BSA and a detergent such as TritonX-100 or Nonidet P40. During the flow step, depending on the geometry of the channels and the buoyancy of the beads, the particles that have bound the relevant entities are sorted into the relevant channels for detection and/or separation. Briefly, when within a particular conduit a bead has a density inferior to the fluid in which it is surrounded, it will migrate to the superior surface of the conduit. When the conduit opens to communicate with the conduit situated directly above it, the bead can migrate into this conduit according to its lower density. Should the bead be neutrally buoyant in this system, it will remain in the conduit. The process takes place in a similar manner for all the conduits, until all the different batches of beads with differing densities are sorted, with their attached analytes. If the mechanism is purely used to separate the beads, they are taken to a collection chamber where further processing, if that is required, can take place. The density of the fluids and beads may be from 1 to 1.3 g/cm3.
If the beads are taken to a detection point or biosensor, they are flowed past it again at a low flow rate. The biosensor is equipped with antibodies raised against another antigenic epitope of the captured analyte. Once bound, the beads that have not bound any biosensor recognition sites are flushed away using a wash solution, similar to that mentioned above.
Detection
If the beads are fluorescent they can be detected and counted immediately using a microscope or CCD camera. If the beads are not fluorescent a secondary antibody, raised to the primary antibody used on the bead, tagged with fluorescent molecule or an enzyme capable of generating a chemiluminescent signal (such as horseradish peroxidase—HRP) can be used (impedence methods, or enzymatic electrochemical detection methods may also be employed). This is flowed over the bead complex at a concentration of approximately 0.5 μg/ml. It is important that the secondary antibody does not cross-react or recognise the biosensor recognising entity. Detection is achieved by measuring the fluorescence emitted by the reaction using a microscope or a CCD camera.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0701641.3 | Jan 2007 | GB | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2008/051040 | 1/29/2008 | WO | 00 | 10/2/2009 |
